NASDAQ · Biotechnology

PBYI (PBYI) Stock

$8.91 +9.73% NASDAQ: PBYI Healthcare

Valuation

MetricValue
Price$8.91
Market Cap$453.51M
P/E Ratio11.46
P/B Ratio2.74
P/S Ratio1.58
EPS (TTM)$0.61
52-Week High$8.91
52-Week Low$3.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE23.85%
ROA14.35%
ROCE28.46%
Gross Margin16.23%
Operating Margin16.23%
Net Margin10.73%
Debt/Equity0.12
Current Ratio2.01

Annual Financials (USD)

Metric20212022202320242025
Revenue$253.0M$228.0M$236.0M$230.0M$228.0M
Operating Profit$1.0M$24.0M$33.0M$31.0M$37.0M
Net Profit$-29.0M$0$22.0M$30.0M$31.0M
EPS$-0.72$0.02$0.45$0.62$0.61
Op Margin0.5%10.4%13.8%13.4%16.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$227.0M$222.0M$231.0M$213.0M$216.0M
Total Liabilities$229.0M$200.0M$177.0M$121.0M$86.0M
Cash$63.0M$76.0M$85.0M$69.0M$30.0M
Borrowings$117.0M$114.0M$111.0M$74.0M$29.0M

Latest News

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 2, 2026 Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why Zacks · Jun 11, 2026 Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings Simply Wall St. · May 14, 2026 Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00 Simply Wall St. · May 11, 2026 Puma (PBYI) Q1 2026 Earnings Call Transcript Motley Fool · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$21.0M$-16.0M$27.0M$39.0M$42.0M
Investing Cash Flow$-11.0M$0$-32.0M$-20.0M$-36.0M
Financing Cash Flow$-30.0M$0$0$-1.0M$-1.0M
Net Cash Flow$-22.0M$4.0M$8.0M$-15.0M$-40.0M
Free Cash Flow$21.0M$-23.0M$14.0M$39.0M$42.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA7.39
FCF Yield14.94%
Quick Ratio2.38
Interest Coverage5.29
Return 1Y132.17%
Return 3Y125.63%
Return 5Y3.83%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABEO $7.14 +3.48% 5.14 $406.94M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
ELDN $3.69 +6.65% -4.85 $284.82M 0.00%

About PBYI

PBYI is led by CEO Alan H. Auerbach, employs 172 people, headquartered in US, publicly traded since 2012.

PBYI stock trades at $8.91 with a market capitalization of $453.51M. The stock is valued at a price-to-earnings (P/E) ratio of 11.46, price-to-book of 2.74, price-to-sales of 1.58. Over the past 52 weeks the stock has ranged between $3.03 and $8.91, and currently trades at its 52-week high.

On profitability, PBYI generates a return on equity (ROE) of 23.85% — well above the market average, a sign of a high-quality business, return on capital employed of 28.46%, an operating margin of 16.23%, a net profit margin of 10.73%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides